Andrews MC, Chen WS, Spencer C, et al. Molecular, immune and microbial predictors of response and toxicity to combination immune-checkpoint blockade (CICB) in melanoma (MEL) patients. SMR 2017, abstract SMR02-3.
Adjuvant alectinib verbetert DFS, maar effect op OS nog onduidelijk
mei 2024 | Longoncologie